CLX

Clorox Co

Add to Watchlist

Advanced Chart

130.810

-0.61(-0.464%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

131.860

Open

131.450

VWAP

130.78

Vol

1.29M

Mkt Cap

16.12B

Low

130.140

Amount

168.33M

EV/EBITDA(TTM)

14.48

Total Shares

124.19M

18.60B

EV/OCF(TTM)

18.11

P/S(TTM)

2.32

The Clorox Company is a multinational manufacturer and marketer of consumer and professional products. The Company operates through four segments: Health and Wellness, Household, Lifestyle, and International. Its Health and Wellness segment consists of cleaning, disinfecting and professional products marketed and sold under the Clorox, Clorox2, Pine-Sol, Scentiva, Tilex, Liquid-Plumr and Formula 409 brands in the United States. Its Household segment consists of bags and wraps, cat litter and grilling products marketed and sold under the Glad, Fresh Step and Scoop Away, and Kingsford brands in the United States. The lifestyle segment consists of food, water-filtration and natural personal care products marketed and sold under the Hidden Valley, Brita and Burt’s Bees brands. International consists of products sold outside the United States. Its products within this segment include laundry additives, home care products, bags and wraps, cat litter, water-filtration products and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q1

FY2025Q4

1.68B

-0.45%

1.548

-0.13%

1.56B

-11.26%

1.549

-16.71%

1.93B

+1.51%

2.196

+20.66%

Estimates Revision

The market is revising Downward the revenue expectations for The Clorox Company (CLX) for FY2025, with the revenue forecasts being adjusted by -0.68% over the past three months. During the same period, the stock price has changed by -5.74%.

Revenue Estimates for FY2025

Revise Downward

-0.68%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.07%

In Past 3 Month

Stock Price

Go Down

-5.74%

In Past 3 Month

14 Analyst Rating

9.45% Upside

Wall Street analysts forecast CLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLX is 143.17 USD with a low forecast of 134.00 USD and a high forecast of 154.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

10 Hold

3 Sell

Hold

9.45% Upside

Current: 130.810

Low

134.00

Averages

143.17

High

154.00

9.45% Upside

Current: 130.810

Low

134.00

Averages

143.17

High

154.00

JPMorgan

Andrea Teixeira

Neutral

downgrade

$144 -> $140

2025-07-25

New

Reason

JPMorgan

Andrea Teixeira

Price Target

$144 -> $140

2025-07-25

New

downgrade

Neutral

Reason

JPMorgan analyst Andrea Teixeira lowered the firm's price target on Clorox to $140 from $144 and keeps a Neutral rating on the shares as part of a quarterly earnings preview. The firm expects another challenging quarter for most names in the household and personal care sector.

UBS

Neutral

downgrade

$150 -> $134

2025-07-17

Reason

UBS

Price Target

$150 -> $134

2025-07-17

downgrade

Neutral

Reason

UBS lowered the firm's price target on Clorox to $134 from $150 and keeps a Neutral rating on the shares.

Citi

Filippo Falorni

Neutral

downgrade

$140 -> $135

2025-07-15

Reason

Citi

Filippo Falorni

Price Target

$140 -> $135

2025-07-15

downgrade

Neutral

Reason

Citi analyst Filippo Falorni lowered the firm's price target on Clorox to $135 from $140 and keeps a Neutral rating on the shares. The firm adjusted price targets in the beverages, household and personal care group as part of a Q2 preview. It sees a slightly improved fundamentals across the sector heading into the reports relative to Q1.

Barclays

Lauren Lieberman

Underweight

downgrade

$129 -> $119

2025-07-15

Reason

Barclays

Lauren Lieberman

Price Target

$129 -> $119

2025-07-15

downgrade

Underweight

Reason

Barclays analyst Lauren Lieberman lowered the firm's price target on Clorox to $119 from $129 and keeps an Underweight rating on the shares. The firm adjusted price targets in the staples group as a part of a Q2 preview. Investor expectations "feel subdued" into earnings season, the analyst tells investors in a research note.

Wells Fargo

Equal Weight

downgrade

$142 -> $135

2025-07-09

Reason

Wells Fargo

Price Target

$142 -> $135

2025-07-09

downgrade

Equal Weight

Reason

Wells Fargo lowered the firm's price target on Clorox to $135 from $142 and keeps an Equal Weight rating on the shares. The firm is aggregating models across Beverage/Food/HPC and updating price targets. With soft consumption data and a likely reset to estimates ahead, Wells thinks the stock will struggle with multiple expansion until visibility on consumption trends improves.

Jefferies

Buy

downgrade

$167 -> $145

2025-06-26

Reason

Jefferies

Price Target

$167 -> $145

2025-06-26

downgrade

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Clorox Co (CLX.N) is 19.47, compared to its 5-year average forward P/E of 27.27. For a more detailed relative valuation and DCF analysis to assess Clorox Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

27.27

Current PE

19.47

Overvalued PE

32.41

Undervalued PE

22.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

17.77

Current EV/EBITDA

13.89

Overvalued EV/EBITDA

20.29

Undervalued EV/EBITDA

15.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.73

Current PS

2.37

Overvalued PS

3.14

Undervalued PS

2.32